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a  b  s  t  r  a  c  t
A prospective study was conducted in four tertiary hospitals in Argentina and Mexico in
order  to describe the occurrence of Clostridium difﬁcile infection (CDI) in these settings. The
objective was to evaluate the incidence of CDI in at-risk populations in Argentina (one center)
and  Mexico (three centers) and to further explore potential study sites for vaccine develop-
ment  in this region. A prospective, descriptive, CDI surveillance study was conducted among
hospitalized patients aged ≥40 years who had received ≥48 h of antibiotic treatment. Stool
samples  were collected from those with diarrhea within 30 days after starting antibiotics
and  analyzed for toxins A and B by ELISA, and positive samples were  further tested by
toxinogenic  culture and restriction endonuclease analysis type assay. Overall, 466 patients
were enrolled (193 in Argentina and 273 in Mexico) of whom 414 completed the follow-up. Of
these, 15/414 (3.6%) experienced CDI episodes occurring on average 18.1 days after admis-
sion  to hospital and 15.9 days after the end of antibiotics treatment. The incidence rate of
CDI was 3.1 (95% CI 1.7–5.2) per 1000 patient-days during hospitalization, and 1.1 (95% CI
0.6–1.8) per 1000 patient-days during the 30-day follow-up period. This study highlightedthe  need for further evalu
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ab r a z j i n f e c t d
ntroduction
lostridium difﬁcile (CD) is a potentially deadly,1–5 spore-
orming bacterium1 that is emerging as a leading cause of life-
hreatening,  healthcare-acquired infections worldwide.3–11
athogenic strains of CD produce potent toxins (e.g. toxA, toxB)
hat cause the clinical manifestations in humans known as
ymptomatic  CD infection (CDI),4,8,12,13 especially in vulner-
ble individuals and mostly in hospitals and long-term care
acilities.1,2,5,7,13–18 An increased prevalence of CDI associated
ith an increase in disease severity and mortality has been
ocumented in the United States, Canada and Europe.
Individuals most at-risk for CDI have a generally weakened
ondition,4,7,19,20 have received antibiotics,1,4,7,9,12,15,17,18,21,22
nd are likely to have been hospitalized or residing in long-
erm  care facilities,1,2,7,12,13,15,17,18,22 where they could have
een exposed to environmental spores. Also, age correlates
ith  increased incidence, severity of disease, the likelihood
f  recurrences, and CDI related-death.2–4,7,9,12,13,21–25Despite
he availability of antibiotics to treat CDI, there is a dis-
urbingly large proportion of patients (i.e. 20–30%) who
xperience recurrences of CDI,9,12,13,16,19,20,25 which lead to
e-hospitalizations20 and longer hospital stays.4,18,20,25 Since
ransmission of CD is difﬁcult to control14 and treatment
ptions for CDI are less than ideal,4,13,19,20 vaccination could
e  an efﬁcacious,13,16 cost-effective1,4,17,19,20,24–26 and com-
lementary public health measure12,13 to protect vulnerable
ndividuals from this devastating disease, in whom the
ttributable mortality is 8–15%.3,5 Sanoﬁ Pasteur is develop-
ng  a toxoid vaccine for the prevention of primary CDI in
t-risk  individuals. In addition, a number of other groups, both
ublic  agencies and private corporations, are developing and
valuating  a number of other prophylactic approaches and
anagement strategies.
Data  on the frequency and impact of CDI in Latin Amer-
ca  are sparse6,27–33; however the disease has been reported
rom prospective laboratory surveillance and in outbreaks.6
oreover, more  virulent CD ribotype 027 has been isolated in
osta Rica32 and in Chile.34 We therefore conducted a prospec-
ive  epidemiological study in order to estimate the incidence
f  symptomatic laboratory-conﬁrmed CDI cases in Argentina
nd  Mexico among newly hospitalized patients considered
t  risk (≥40 years of age who have commenced in-hospital













Size of recruitment area 275,000  2 million
Type of institution Tertiary care,
teaching
Tertiary  
Number of specialties 25 31 
Beds 142 200 
Population Adults, children Adults  0 1 5;1 9(1):8–14  9
antibiotic treatment) and to describe the characteristics of
these  patients, as a prelude for potential vaccine trials in this
region.
Materials  and  methods
Type  of  study  and  setting
This study was  a prospective, descriptive, surveillance of
CDI  in hospitalized patients conducted in one hospital in
Argentina  and in three hospitals in Mexico, from September
21,  2010 to September 19, 2011. Study sites are described in
Table  1.
Study  population
Patients aged ≥40 years and who received at least 48 h of
antibiotic  treatment were  included in this study. Excluded
patients were those with CDI within the last three months,
or  who presented with diarrhea at admission or who  received
antibiotics within 30 days prior to admission or started on
antibiotic  treatment beyond 48 h of hospitalization.
Case  deﬁnition
A laboratory-conﬁrmed CDI case was  deﬁned as a patient with
clinical  suspicion of CDI (i.e. antibiotic-associated diarrhea)
and  ELISA test detection of CD toxins A or B. Diarrhea was
deﬁned  as three or more  stools in a 24-h period. A severe CDI
case  was  deﬁned as a laboratory-conﬁrmed CDI case with at
least  two of the following criteria: white blood cell (WBC) count
>15,000/mL,  >50% increase on serum creatinine, temperature
>38.5◦ C, evidence of severe colitis (i.e. abdominal or radiolog-
ical  signs), age at the time of CDI ≥60 years, or hospitalized in
intensive  care unit (ICU) during CDI.
Laboratory  testing
Stool samples were  collected from patients with diarrhea
within 30 days after the start of antibiotic therapy and under-
went  conﬁrmatory laboratory testing using ELISA for C. difﬁcile
toxins  A and B, and toxigenic culture with restriction endonu-
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stool mixed with phosphate buffered saline (PBS) at a dilu-
tion  of 1:40 was  centrifuged, and the supernatant ﬁltered
on  a 0.45 m pore-size ﬁlter, and inoculated on Hep-2 cell
monolayers. Toxigenic culture samples were selected to per-
form  a neutralization assay with Clostridium sordelli anti-
toxin.
Data  collection
Each included patient was  followed up 30 days after the start
of  antibiotic therapy. The following data were  collected for
each  recruited subject: dates of admission and discharge,
demographics, medical history including hospitalizations and
surgeries,  reasons for admission to the hospital, prior history
of  CDI, history of co-morbidities, and history of antibiotics use,
as  well as use of antibiotics, proton pump inhibitors and/or
probiotics throughout the 30-day follow-up period. If applica-
ble,  onset of the ﬁrst CDI episode, and antibiotic treatment for
the CDI episode were also reported.
If a study participant was  discharged from hospital before
the  completion of the 30-day follow-up period, he/she was
given  the material needed for stool sample, instructions on
collection,  and instructions to immediately contact the site in
case of diarrhea. In addition, study staff called the patient’s
home  every three to four days up to the end of the follow-up
period to ask about any occurrence of diarrhea and to rein-
force  the need to report any such occurrences immediately. If
diarrhea occurred, the subject was  asked to bring the sample
to  the study site.
Statistical  analysis
Data were  described using absolute and relative frequencies.
Incidence density rates of conﬁrmed cases were calculated as
the number of CDI cases per 1000 patient days, with their 95%
conﬁdence  interval (CI). These rates were calculated in two
ways,  using either the study follow-up period or the hospital
length  of stay as the risk periods of developing CDI.
Quantitative variables were  compared between groups
using  the Mann–Whitney U-test and categorical variables
using  the Fisher exact test. Statistical analyses were per-
formed  using SAS® 9.2 software, and p-value <0.05 were
considered as statistically signiﬁcant.
Ethics  statement
Protocol and informed consent forms (ICF) were approved by
each institutional ethic committee before study initiation and
ICF  was  obtained before inclusion.
ResultsA total of 466 patients were enrolled in the study and 414 (89%)
completed  the follow-up. Among the 52 (11%) patients who
discontinued the study, the most common reasons for discon-
tinuation  were  death during hospitalization (n = 32; 7%) and
lost  to follow-up (n = 12; 3%).2 0 1 5;1  9(1):8–14
Demographics  and  hospitalization  data
The overall mean [range] age of included patients was  61.4
years  [40; 95], 229 (55%) were  male and 185 (45%) were  female.
The  most frequent reasons for hospitalization during the
study  were  abdominal pain (n = 28; 7%), pneumonia (n = 33; 8%),
cellulitis  (n = 14; 3%), dyspnea (n = 14; 3%), pyrexia (n = 13; 3%),
and  pain in extremity (n = 13; 3%). The mean [range] length of
stay  was  9.0 days [2; 36 days] and at least one procedure or
surgery  was planned for 361 (87%) patients during hospital-
ization.
Description  of  patient  history
No patients had prior history of CDI. Twenty-eight (7%)
patients were hospitalized in the last three months and only
six  (1%) patients were previously hospitalized or were  in a
long-term  care facility within the 30-day period before study
inclusion.
The  majority (n = 279; 67%) of the patients reported taking
medication on a daily basis prior to their admission. Med-
ications  included proton-pump inhibitors (n = 52; 13%), H2
receptor  antagonists (n = 26; 6%), immunosuppressive agents
(n  = 5; 1%), and antibiotics within the last three months (but
excluding  the past 30 days) (n = 25; 6%).
The  most commonly prescribed antibiotics during hos-
pitalization were  third generation cephalosporins for 201
(49%)  patients, ﬂuoroquinolones for 153 (37%) patients,
lincosamides for 98 (24%) patients and ﬁrst generation
cephalosporins for 96 (23%) patients.
Comparison of medication usage is presented in Table 2.
No  difference was  observed between CDI positive and CDI
negative  patients, except for the following antibiotics which
were  signiﬁcantly more  frequently used among laboratory-
conﬁrmed cases than among CDI negative patients: clin-
damycin,  combinations of penicillins (including -lactamase
inhibitors), vancomycin, carbapenems, trimethoprim and
derivatives,  sulfonamides, polymyxins, and penicillins with
extended  spectrum.
Diarrhea  and  laboratory-conﬁrmed  CDI  cases
Table 3 reports estimates of diarrhea and laboratory-
conﬁrmed CDI by country and overall. Thirty-seven (9%)
patients  experienced at least one episode of diarrhea, occur-
ring  in hospital for 30 (81%) patients and at home for eight
(22%)  patients (one patient had two episodes, one in hospital
and  one at home). A total of 15 patients had laboratory-
conﬁrmed CDI, 13 occurring during the stay in hospital and
two  at home; 14 (8%) CDI were  diagnosed in Argentina (includ-
ing  ﬁve severe cases) and one (0.4%) in Mexico (Veracruz).
Overall, CD was  found in 41% (15/37) of diarrhea cases and in
3.6%  (15/414) of patients, but these estimates were  higher in
Argentina  than in Mexico. The overall incidence density was
1.1  (95% CI 0.6–1.8) per 1000 patient-days during the study
follow-up period and 3.1 (95% CI 1.8–5.0) per 1000 patient-
days during hospitalization. Again, these ﬁgures were higher
in  Argentina than in Mexico.
Positive  toxigenic culture was reported for 14 (93%) of
the  15 laboratory-conﬁrmed CDI, concerning 13 patients in
b r a z j i n f e c t d i s . 2 0 1 5;1  9(1):8–14  11
Table 2 – Patient characteristics of laboratory-conﬁrmed and non-laboratory-conﬁrmed Clostridium difﬁcile infection (CDI)
cases.
Patient characteristics Laboratory-
conﬁrmed  CDI cases
n  = 15 (%)
Non-laboratory-
conﬁrmed  CDI cases
n  = 399 (%)
p-value Total
n = 414 (%)
Age (years)
Mean (min–max) 67 (41–92) 61 (40–95) 0.056 61 (40–95)
Sex
Male 8 (53) 221 (55) 0.539 229 (55)
Female 7 (47) 178 (45) 185 (45)
Hospitalization history in the last 3 months
No 13 (87) 373 (94) 0.269 386 (93)
Yes 2 (13) 26 (7) 28 (7)
Proton pump inhibitors
No  12 (80) 349 (88) 0.417 361 (87)
Yes 3 (20) 49 (12) 52 (13)
Unknown 0 1 1
Anti-H2
No 15 (100) 372 (93) 0.613 387 (94)
Yes 0 (0) 26 (7) 26 (6)
Unknown 0 1 1
Immunosuppressors
No 15 (100) 393 (99) >0.999 408 (99)
Yes 0 (0) 5 (1) 5 (1)
Unknown 0 1 1
Antibiotics received in the last 3 months
No  13 (87) 374 (94) 0.229 387 (94)
Yes 2 (13) 23 (6) 25 (6)
Unknown 0 2 2
Antibiotics received prior to onset of CDI
Clindamycin 11 (73) 98 (25) <0.001 98 (24)
3rd-generation cephalosporins 9 (60) 192 (48) 0.436 201 (49)
Combinations of penicillins, including
-lactamase  inhibitors
8  (53) 88 (22) 0.001 96 (23)
Fluoroquinolones 7 (47) 146 (37) 0.427 153 (37)
Vancomycin 5 (33) 16 (4) <0.001 21 (5)
Carbapenems 4 (27) 21 (5) 0.009 25 (6)
Trimethoprim and derivatives 3 (20) 6 (2) 0.003 9 (2)
Sulfonamides 3 (20) 6 (2) 0.003 9 (2)
Nitroimidazole derivatives 4 (27) 72 (18) 0.493 76 (18)
Macrolides 2 (13) 41 (10) 0.662 43 (10)
4th-generation cephalosporins 1 (7) 9 (2) 0.312 10 (2)
Triazole derivatives 1 (7) 4 (1) 0.169 5 (1)
Polymyxins 1 (7) 0 (0) 0.036 1 (0)











rUnspeciﬁed antibiotics 1 (7) 
Aminoglycosides 1 (7) 
rgentina and one patient in Mexico. Among the 13 Argen-
inean  patients, 11 (85%) patients were infected with C. difﬁcile
EA  type CF group and two (15%) patients were infected with
H  group and Y group, respectively. A non-speciﬁc REA type
as  identiﬁed in the Mexican patient.
The median [range] time interval between admission and
he  ﬁrst CDI episode was  18.1 days [3; 30] and the median
range] duration of antibiotics between onset of antibiotic ther-
py and the ﬁrst CDI episode was  15.9 days [1; 28].According to the deﬁnition, ﬁve (33%) severe CDI were
bserved among the 15 laboratory-conﬁrmed CDI patients.
hey  had an average of ﬁve diarrhea within 24 h [3; 8] and
eported  clinical symptoms included abdominal pain (n = 3),59 (15) 0.707 60 (14)
3 (1) 0.138 4 (1)
malaise (n = 3), watery diarrhea (n = 3), abdominal distention
(n  = 2), fever ≥38 ◦C (n = 2), loss of appetite (n = 2), weight loss
(n  = 2) and hypotension (n = 1).
Discussion
This prospective multicenter study conﬁrmed the presence
of  CDI in at-risk patients hospitalized in tertiary centers in
Argentina  and Mexico, with an incidence of 1.1 per 1000
patient  days within 30 days after initiation of antibiotic
treatment. CDI episodes also occurred after discharge from
hospital,  suggesting that follow-up of at-risk patients is
12  b r a z j i n f e c t d i s . 2 0 1 5;1  9(1):8–14














Number of patients 168 246 414
Number of patients-days 5385 1875 8251 2319 13,636 4194
Number of diarrhea
episodes
24 20 13 10 37 30
Number of
laboratory-conﬁrmed CDI
14  12 1 1 15 13
% of diarrhea episodes
among  patients
14% 12% 5% 4% 9% 7%
% of laboratory-conﬁrmed
CDI  among patients with
diarrhea
8% 7% 0.4% 0.4% 4% 3%
% of laboratory-conﬁrmed
CDI  during diarrhea
episodes
58% 60% 8% 10% 41% 43%
.1 
0.01–Incidence rate per 1000
patients-days  (95% CI)
2.6 6.4 0
(1.5–4.3) (3.5–10.9) (
essential to estimate the rate of CDI. In addition, the REA CF
group  observed predominantly in this study is also known as
ribotype 017 and toxinotype VIII and was  previously reported
in  outbreaks worldwide.15
Data on the frequency and impact of CDI in Latin Amer-
ica  are sparse and comparison between studies is difﬁcult
due  to the variety of study designs. One study conducted
among 113 patients in Mexico and Latin America from 2003
to  200727 identiﬁed use of H2 blockers, prior hospitalization
within 12 weeks of diagnosis, prior use of cephalosporins and
ﬂuoroquinolones, stay at an ICU, extended hospital stay, and
antimicrobial  use before diagnosis as risk factors for CDI. In
our  study, neither cephalosporins nor ﬂuoroquinolones were
found  associated with CDI. From 1998 to November 1999, 245
fecal  specimens from hospitalized and ambulatory patients
were  tested to conﬁrm the diagnosis of CDI in a medical cen-
ter  in Buenos Aires (28, 29) and 16 (6.5%) were identiﬁed as
positive  by isolation of cytotoxigenic CD among hospitalized
patients (81.3%) and outpatients (18.7%) with a mean age of
72.9  years. All patients had received two or more  antimicrobial
agents, mainly beta-lactams, two months before the appear-
ance  of diarrhea. In Argentina, 104 consecutive stool samples
from  87 patients with diarrhea were  screened for toxigenic CD
between April 2000 and April 2001.31,33 The study reported that
38.5%  of the samples and 36.8% of the patients were positive
for  CD. Another study performed in a 200-bed general hospi-
tal  in Buenos Aires35 showed incidence rates of CDI ranging
from  37 to 84 per 10,000 admissions between years 2000 and
2005.  Finally, Quesada-Gomez and co-workers32 reported the
emergence  of CD NAP1 strain in a Costa Rican hospital.
Some limits and strengths of this descriptive study should
be  discussed. Data were  collected in two geographical areas
and  four centers, which may  limit the generalization of the
risk  estimates to Latin America. Outbreaks have been pre-
viously  reported in Brazil and Argentina6 and ribotype 027
was  already isolated in Costa Rica32 and in Chile.34 This sug-
gested  that CDI could tend to occur in outbreaks in Argentina,
and  this may  explain why more  cases were observed in this
country  than in Mexico after only one year of surveillance.0.4 1.1 3.1
0.6) (0.02–0.2) (0.6–1.8) (1.7–5.2)
Therefore, a longer surveillance period over a larger number
of  study sites and countries may  be needed in order to have
a  more  generalizable estimation of CDI in the region. In our
study,  results were consolidated by the prospective nature of
the  study design with laboratory conﬁrmation of CDI using
two  complementary laboratory techniques (ELISA and REA).
While  polymerase chain reaction (PCR)-based methods may
have  allowed for an increased detection rate of toxigenic C.
difﬁcile  than ELISAs for Toxin A and B, such methods were  not
in  routine practice at the sites at the time of this study. In addi-
tion,  these methods may  fail to discriminate between CDI  and
asymptomatic  colonization with C. difﬁcile, potentially lead-
ing  to an over detection of cases whereas ELISA-based toxin
testing  offers strong evidence of clinical disease despite its
shortcomings with regards to sensitivity.36
While antibiotic therapy using ﬁdaxomicin (approved in
2011  and not available at the time of this study), metronida-
zole,  vancomycin, and rifampicin is often used in treating the
principal  episodes of diarrhea, these agents are of no beneﬁt
in  the treatment of asymptomatic carriers and in the erad-
ication  of spores, which are the main transmissible form of
this  organism.37,38 In addition, 20% of patients treated with
metronidazole or vancomycin will have a symptomatic recur-
rence  when treatment is discontinued, and are at increased
risk  for multiple recurrences.12 Patients who suffer two recurr-
ences  have an approximate risk of 65% for further recurrence
of  CDI, and this form of CDI is a substantial clinical man-
agement problem.37 The limitations of conventional therapy,
the  incongruity of treating antibiotic-associated diarrhea with
additional  antibiotics, the rapid increase in the incidence of
CDI  over the past decade, and the risk of inducing antibiotic
resistance, require the development of new strategies to limit
the  impact of this opportunistic pathogen.15
In conclusion, the results of this study added further
elements to the existing but limited data regarding CDI in
Argentina  and Mexico. Caution should be exercised when
extrapolating these data to the country level or to Latin Amer-
ica  as a whole due to the epidemiological heterogeneity of the
disease  within and across countries in that region. However,
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